कंपनी का अवलोकन
Evolent Health, Inc. operates as a specialized entity within the healthcare sector, specifically focusing on the health information services industry. Through its subsidiary, the company delivers specialty care management services across oncology, cardiology, and musculoskeletal markets throughout the United States. Additionally, it provides an integrated value-based care platform designed for health plan administration and management, alongside administrative services. The organization employs approximately 4,200 individuals and maintains a total market capitalization of $272.40M while reporting trailing twelve-month revenue of $1.88B. These valuation and revenue figures indicate that the company holds a significant operational scale within its niche, yet the relatively low market cap relative to its revenue suggests a specific market positioning or investor sentiment that differs from larger-cap healthcare peers.
वित्तीय स्वास्थ्य
The financial performance of Evolent Health, Inc. is characterized by a revenue stream of $1.88B over the trailing twelve months, a net income loss of $579,401,024, and an EBITDA of $88.22M. The substantial gap between the positive EBITDA and the negative net income reveals a heavy cost structure involving significant interest expenses or other non-operating costs that erode overall profitability. Despite the net loss, the company generates a free cash flow of $98.41M, which provides a degree of financial flexibility to fund operations and potential strategic initiatives without immediate reliance on external financing. Profitability analysis shows a gross margin of 21.3%, an operating margin of -2.1%, and a profit margin of -28.5%, indicating that while the core operations retain some value, overhead costs and interest obligations severely impact the bottom line. The balance sheet presents a complex picture with cash reserves of $151.86M against total debt of $989.70M, resulting in a debt-to-equity ratio of 238.37, which signifies a highly leveraged position rather than a conservative one. Liquidity is assessed through a current ratio of 1.31, suggesting the company possesses sufficient current assets to cover short-term liabilities, though the margin is not excessively wide. Return on equity stands at -66.5% and return on assets is -0.1%, metrics that reveal management is currently unable to generate positive returns on the capital invested or the assets employed by the firm.
मूल्यांकन आकलन
Valuation metrics for Evolent Health, Inc. display a divergence between historical earnings and future expectations, with a trailing P/E ratio listed as N/A due to the recent net losses, while the forward P/E ratio is projected at 5.52. This difference implies that the market prices the stock based on anticipated future earnings recovery rather than current profitability, suggesting a high-stakes turnaround narrative. The price-to-book ratio is recorded at 0.66, indicating that the market values the company at significantly less than its book value, which often signals undervaluation or concerns regarding asset quality and future earnings potential. Alternative valuation measures include a price-to-sales ratio of 0.15 and an EV/EBITDA of 12.59, suggesting the market is willing to pay a modest multiple of sales relative to the company's enterprise value and earnings before interest, taxes, depreciation, and amortization. Price action over the last year ranges from a low of $2.10 to a high of $12.06, meaning the current share price sits at a level that reflects the recent volatility and market re-rating of the stock. The beta coefficient is 0.37, which indicates that the stock exhibits low price volatility and is less sensitive to movements in the broader market compared to high-beta equities.
Growth & Income
Growth metrics show a revenue decline of 27.5% year-over-year and earnings growth listed as N/A, reflecting the company's current financial distress rather than expansion. Since the earnings growth rate is unavailable due to negative net income, the traditional comparison of earnings growing faster than revenue cannot be calculated, but the revenue contraction itself points to a challenging operational environment. Regarding income distribution, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that it does not distribute dividends to shareholders. Instead of paying dividends, the company retains its earnings, albeit negative in the current period, to service its debt obligations and maintain liquidity. The overall growth and income profile is defined by significant revenue contraction and a complete absence of dividend income, positioning the stock as a speculative play on potential future recovery rather than a vehicle for current yield or stable growth.